← Home
Shionogi 
Pharma / Pharmaceuticals and Healthcare
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-04-01 19:30:00 | Shionogi Completes Acquisition Of All Rights To Radicava (edaravone) Osaka, japan--(business wire)--shionogi & co., ltd. (head office: osaka, japan; chief executive officer: isao teshirogi, ph.d.; hereafter “shionogi”) announced that we have completed the transfer of all rights for radicava (edaravone), including intellectual property rights and sales rights, in major countries and regions to our company from tanabe pharma corporation. transfer of rights in additional countries and regions is forthcoming. the acquisition and integration of radicava team memb. |
| 2026-03-19 08:45:00 | Shionogi Announces First Patients Enrolled In Global Phase 2 Clinical Trial In Adults With Late-onset Pompe Disease Osaka, japan--(business wire)--shionogi & co., ltd. (head office: osaka, japan; chief executive officer: isao teshirogi, ph.d.; hereafter “shionogi”) announced the first patients were enrolled in esprit, a global phase 2 clinical trial evaluating s-606001, an investigational drug for the treatment of late-onset pompe disease (lopd). esprit is a multicenter, randomized, placebo-controlled, double-blind study evaluating the safety, pharmacodynamics and preliminary efficacy of s-606001 as an o. |
📰 Browse additional press releases for Shionogi!
Sign up for free or log in📝 Join us and grab your copy of "The Checklist Value Investor — A Smarter Way to Pick Stocks"